Insider · CIK 0001577061

Sandrock Alfred

Reports to the SEC for 3 companies · LEXINGTON, MA

sec.gov

Transactions

Companies

Filings

CIK

0001577061

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-04-02	VYGRVoyager Therapeutics, Inc.S Sale	Director, President and CEO	SSale	−11.5K sh	$3.87	−$44.5K	472,549
2026-02-24	VYGRVoyager Therapeutics, Inc.S Sale	Director, President and CEO	SSale	−14.2K sh	$3.79	−$53.8K	484,060
2026-02-18	VYGRVoyager Therapeutics, Inc.S Sale	Director, President and CEO	SSale	−11.7K sh	$3.41	−$40K	498,257
2026-02-10	VYGRVoyager Therapeutics, Inc.S Sale	Director, President and CEO	SSale	−12.2K sh	$3.78	−$46.1K	509,989
2026-02-06	VYGRVoyager Therapeutics, Inc.A Award	Director, President and CEO	AAward	+86.3K sh	—	—	522,181
2026-02-06	VYGRVoyager Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+403K sh	—	—	402,500
2025-04-02	VYGRVoyager Therapeutics, Inc.S Sale	Director, President and CEO	SSale	−10.9K sh	$3.43	−$37.3K	430,931
2025-02-21	VYGRVoyager Therapeutics, Inc.A Award	Director, President and CEO	AAward	+145K sh	—	—	441,816
2025-02-21	VYGRVoyager Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+290K sh	—	—	290,000
2025-02-20	VYGRVoyager Therapeutics, Inc.S Sale	Director, President and CEO	SSale	−11.7K sh	$4.24	−$49.6K	296,816
2025-02-11	VYGRVoyager Therapeutics, Inc.S Sale	Director, President and CEO	SSale	−16.6K sh	$4.45	−$74.1K	308,518
2024-04-02	VYGRVoyager Therapeutics, Inc.S Sale	Director, President and CEO	SSale	−12.1K sh	$9.86	−$119K	322,839
2024-02-21	VYGRVoyager Therapeutics, Inc.S Sale	Director, President and CEO	SSale	−13K sh	$7.46	−$97.2K	334,954
2024-02-09	VYGRVoyager Therapeutics, Inc.A Award	Director, President and CEO	AAward	+130K sh	—	—	347,987
2024-02-09	VYGRVoyager Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+260K sh	—	—	260,000
2023-04-03	VYGRVoyager Therapeutics, Inc.S Sale	Director, President and CEO	SSale	−7,437 sh	$7.83	−$58.2K	214,618
2023-02-17	VYGRVoyager Therapeutics, Inc.A Award	Director, President and CEO	AAward	+120K sh	—	—	222,055
2023-02-17	VYGRVoyager Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+240K sh	—	—	240,000
2022-03-22	VYGRVoyager Therapeutics, Inc.A Award	Director, President and CEO	AAward	+100K sh	—	—	100,000
2022-03-22	VYGRVoyager Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+941K sh	—	—	940,600
2022-02-07	VYGRVoyager Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+44K sh	—	—	44,000
2021-06-07	BIIBBIOGEN INC.S Sale	Head of Research & Development	SSale	−7,672 sh	$440.00	−$3.38M	10,169.112
2021-02-18	BIIBBIOGEN INC. · Restricted Stock UnitA Award	Head of Research & Development	AAward	+14.5K sh	—	—	14,500
2021-02-12	BIIBBIOGEN INC.F Tax Payment	Head of Research & Development	FTax Payment	−1,533 sh	$278.03	−$426K	15,261.21
2021-02-12	BIIBBIOGEN INC.M Exercise/Conversion	Head of Research & Development	MExercise/Conversion	+1,300 sh	—	—	16,561.21
2021-02-12	BIIBBIOGEN INC.M Exercise/Conversion	Head of Research & Development	MExercise/Conversion	+1,446 sh	—	—	18,007.21
2021-02-12	BIIBBIOGEN INC.M Exercise/Conversion	Head of Research & Development	MExercise/Conversion	+1,708 sh	—	—	19,715.21
2021-02-12	BIIBBIOGEN INC.F Tax Payment	Head of Research & Development	FTax Payment	−577 sh	$278.03	−$160K	19,138.21
2021-02-12	BIIBBIOGEN INC.F Tax Payment	Head of Research & Development	FTax Payment	−642 sh	$278.03	−$178K	18,496.21
2021-02-12	BIIBBIOGEN INC.F Tax Payment	Head of Research & Development	FTax Payment	−758 sh	$278.03	−$211K	17,738.21
2021-02-12	BIIBBIOGEN INC. · Restricted Stock UnitM Exercise/Conversion	Head of Research & Development	MExercise/Conversion	−1,300 sh	—	—	1,466
2021-02-12	BIIBBIOGEN INC. · Restricted Stock UnitJ Other	Head of Research & Development	JOther	−1,466 sh	—	—	0
2021-02-12	BIIBBIOGEN INC. · Restricted Stock UnitM Exercise/Conversion	Head of Research & Development	MExercise/Conversion	−1,446 sh	—	—	5,442
2021-02-12	BIIBBIOGEN INC. · Restricted Stock UnitJ Other	Head of Research & Development	JOther	−1,996 sh	—	—	3,446
2021-02-12	BIIBBIOGEN INC. · Restricted Stock UnitM Exercise/Conversion	Head of Research & Development	MExercise/Conversion	−1,708 sh	—	—	10,352
2021-02-12	BIIBBIOGEN INC. · Restricted Stock UnitJ Other	Head of Research & Development	JOther	−2,310 sh	—	—	8,042
2021-01-27	BIIBBIOGEN INC.A Award	Head of Research & Development	AAward	+3,728 sh	—	—	16,794.21
2020-11-04	BIIBBIOGEN INC.S Sale	Head of Research & Development	SSale	−1,500 sh	$350.00	−$525K	13,066.21
2020-02-15	BIIBBIOGEN INC.M Exercise/Conversion	Head of Research & Development	MExercise/Conversion	+1,213 sh	—	—	15,019.245
2020-02-15	BIIBBIOGEN INC.F Tax Payment	Head of Research & Development	FTax Payment	−538 sh	$333.00	−$179K	14,481.245
2020-02-15	BIIBBIOGEN INC. · Restricted Stock UnitM Exercise/Conversion	Head of Research & Development	MExercise/Conversion	−1,213 sh	—	—	915
2020-02-15	BIIBBIOGEN INC. · Restricted Stock UnitJ Other	Head of Research & Development	JOther	−915 sh	—	—	0
2020-02-12	BIIBBIOGEN INC.M Exercise/Conversion	Head of Research & Development	MExercise/Conversion	+2,211 sh	—	—	12,702.245
2020-02-12	BIIBBIOGEN INC.F Tax Payment	Head of Research & Development	FTax Payment	−660 sh	$331.76	−$219K	12,042.245
2020-02-12	BIIBBIOGEN INC.M Exercise/Conversion	Head of Research & Development	MExercise/Conversion	+1,422 sh	—	—	13,464.245
2020-02-12	BIIBBIOGEN INC.F Tax Payment	Head of Research & Development	FTax Payment	−538 sh	$331.76	−$178K	12,926.245
2020-02-12	BIIBBIOGEN INC.M Exercise/Conversion	Head of Research & Development	MExercise/Conversion	+1,583 sh	—	—	14,509.245
2020-02-12	BIIBBIOGEN INC.F Tax Payment	Head of Research & Development	FTax Payment	−703 sh	$331.76	−$233K	13,806.245
2020-02-12	BIIBBIOGEN INC. · Restricted Stock UnitM Exercise/Conversion	Head of Research & Development	MExercise/Conversion	−2,211 sh	—	—	0
2020-02-12	BIIBBIOGEN INC. · Restricted Stock UnitM Exercise/Conversion	Head of Research & Development	MExercise/Conversion	−1,422 sh	—	—	4,106

Recent filings

Accepted (ET)
Apr 34
Sandrock Alfred0001104659-26-039691
SEC(opens sec.gov)
Feb 264
Sandrock Alfred0001104659-26-020181
SEC(opens sec.gov)
Feb 204
Sandrock Alfred0001104659-26-018126
SEC(opens sec.gov)
Feb 114
Sandrock Alfred0001104659-26-013414
SEC(opens sec.gov)
Feb 104
Sandrock Alfred0001104659-26-012672
SEC(opens sec.gov)
Apr 44
Sandrock Alfred0001104659-25-032202
SEC(opens sec.gov)
Feb 244
Sandrock Alfred0001104659-25-016520
SEC(opens sec.gov)
Feb 124
Sandrock Alfred0001104659-25-012196
SEC(opens sec.gov)
Apr 34
Sandrock Alfred0001104659-24-043104
SEC(opens sec.gov)
Feb 224
Sandrock Alfred0001104659-24-026561
SEC(opens sec.gov)
Feb 164
Sandrock Alfred0001104659-24-024982
SEC(opens sec.gov)
Apr 54
Sandrock Alfred0001104659-23-042230
SEC(opens sec.gov)
Feb 224
Sandrock Alfred0001104659-23-024418
SEC(opens sec.gov)
Mar 234
Sandrock Alfred0001104659-22-037149
SEC(opens sec.gov)

Companies

Address

C/O VOYAGER THERAPEUTICS, INC. 75 HAYDEN AVENUE

LEXINGTON, MA, 02421